# C3i at ISCT 2025: An International Showcase for Our CDMO Capabilities \- CentreC3i

**URL:** [View](https://c3i.creativedotdesign.com/c3i-at-isct-2025-an-international-showcase-for-our-cdmo-capabilities/)

**Last Updated:** 2025-06-10T16:26:24+00:00

**Other languages:** [Français](https://c3i.creativedotdesign.com/fr/c3i-a-isct-2025-une-vitrine-internationale-pour-nos-capacites-cdmo/)

***A strategic gathering at the crossroads of innovation, regulation, and global partnerships***

From May 7 to 10, 2025, C3i participated in the **International Society for Cell & Gene Therapy (ISCT)**, a major global conference held this year in New Orleans. Bringing together leading experts and organizations in the field, ISCT serves as a key hub for advancing cell and gene therapies. C3i proudly showcased its integrated CDMO offering with a strong message:

We are the **first Canadian CDMO authorized by Health Canada for commercial manufacturing of cell therapies**, and now also **approved by the EMA** to manufacture cell therapy products for the European market.

With this dual regulatory recognition, C3i offers its partners **local expertise of the Cold Chain Logistic**, combining quality, compliance, and accelerated time-to-market. Our representatives, Jamie Sharp, Ph.D., and Cynthia Thérien, engaged with numerous industry leaders at booth #545, emphasizing the importance of building strong bridges between regulation, production, and innovation.

ISCT 2025 represents a significant milestone for C3i’s global reach and reinforces our commitment to cutting-edge manufacturing in service of patients worldwide.